Volume 11, Issue 2 (4-2013)                   IJRM 2013, 11(2): 133-0 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Eftekhar M, Rahmani E, Mohammadian F. Comparison of pregnancy outcome in half-dose Triptorelin and short-acting Decapeptyl in long protocol in ART cycles: A randomized clinical trial. IJRM. 2013; 11 (2) :133-0
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-384-en.html
1- Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , rahmani@bpums.ac.ir
2- Department of Obstetrics and Gynecology, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Obstetrics and Gynecology, Zanjan University of Medical Sciences, Zanjan, Iran
Abstract:   (1493 Views)
Background: Gonadotrophin-releasing hormone (GnRH) agonist is used for controlling ovarian stimulation in assisted reproductive technology (ART) cycles which has some benefits.
Objective: To compare the efficacy of two different formulations of GnRH agonist: short-acting and long-acting, for ART protocols.
Materials and Methods: In a prospective randomized study, one hundred women who underwent ART cycles were randomly divided into two groups. In group I, the patients received one single injection of 1.87 mg Triptorelin in previous mid-luteal phase. In group II, Decapeptyl 0.1 mg per day started from previous mid-luteal phase. Pregnancy outcome in in vitro fertilization (IVF) cycle was compared between two groups.
Results: There were no statistically significant differences in the number of retrieved oocyte (p=0.545), fertilization (p=0.876), implantation (p=0.716) and pregnancy rate (p=0.727) between the two groups.
Conclusion: There were not any advantages in IVF outcome between half-dose long-acting and short-acting GnRH agonist groups in ART cycle.
Full-Text [PDF 454 kb]   (322 Downloads) |   |   Full-Text (HTML)  (139 Views)  
Type of Study: Original Article |

References
1. Dal Prato L, Borini A, Coticchio G, Cattoli M, Flamigni C. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study. Hum Reprod 2004; 19: 2200-2205. [DOI:10.1093/humrep/deh415]
2. Yim SF, Lok IH, Cheung LP, Briton-Jones CM, Chiu TTY, Haines CJ. Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF. Hum Reprod 2001; 16: 492-494. [DOI:10.1093/humrep/16.3.492]
3. Hsieh YY, Chang CC, Tsai HD. Comparisons of Different Dosages of Gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan J Obstet Gynecol 2008; 47: 66-74. [DOI:10.1016/S1028-4559(08)60057-1]
4. Isikoglu M, Ozdem S, Berkkanoglu M, Jamal H, Senturk Z, Ozgur K. Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles. Hum Reprod 2007; 22: 1657-1661. [DOI:10.1093/humrep/dem054]
5. Cheon KW, Song SJ, Choi BC, Lee SC, Lee HB, Yu SY, et al. Comparison of clinical efficacy between a single administration of long-acting gonadotrophin-releasing hormone agonist (GnRHa) and daily administrations of short-acting GnRHa in in vitro fertilization-embryo transfer cycles. J Korean Med Sci 2008; 23: 662-666. [DOI:10.3346/jkms.2008.23.4.662]
6. Parinaud J, Beaur A, Bourreau E, Vieitez G, Pontonnier G. Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cell. Int J Gynecol Obstet 1989; 28: 389-389. [DOI:10.1016/0020-7292(89)90616-4]
7. Dal Prato L, Borini A, Cattoli M, Bonu MA, Sereni E, Flamigni C. GnRH analogs: depot versus short formulations. Eur J Obstet Gynecol Reprod Biol 2004; 115: 40-43. [DOI:10.1016/j.ejogrb.2004.01.014]
8. El-Nemr A, Bhide M, Khalifa Y, Al-Mizyen E, Gillott C, Lower AM, et al. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study. Eur J Obstet Gynecol Reprod Biol 2002; 103: 140-145. [DOI:10.1016/S0301-2115(01)00297-4]
9. Geber S, Sales L, Sampaio MAC. Comparison between a single dose of Goserelin (Depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: A clinical endocrinological study of the ovarian response. J Assist Reprod Genet 2002; 19: 313-318. [DOI:10.1023/A:1016054424966]
10. Albuquerque L, Saconato H, Maciel M. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev 2002; (3): CD002808.
11. Pang SC. A pen injection device for self-administration of recombinant follicle-stimulating hormone for fertility treatments. Exp Rev Med Devices 2005; 2: 27-32. [DOI:10.1586/17434440.2.1.27]
12. Tsai HD, Chen CM, Lo HY, Chang CC. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. Hum Reprod 1995; 10: 2909-2912. [DOI:10.1093/oxfordjournals.humrep.a135817]
13. Marcus SF, Ledger WL. Efficacy and safety of long-acting GnRH agonists in in vitro fertilization and embryo transfer. Hum Fertil (Camb) 2001; 4: 85-93. [DOI:10.1080/1464727012000199351]
14. Gonen Y, Dirnfeld M, Goldman S, Koifman M, Abramovici H. The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF). J In Vitro Fert Embryo Transf 1991; 8: 254-259. [DOI:10.1007/BF01139780]
15. Safdarian L, Mohammadi FS, Alleyassin A, Aghahosseini M, Meysamie A, Rahimi E. Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916). Hum Reprod 2007; 22: 2449-2454. [DOI:10.1093/humrep/dem223]
16. Tehraninejad ES, Nekoo EA, Ezabadi Z, Rashidi BH, Amirchaghmaghi E, Matroud EP. Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles. Arch Med Sci 2010; 6: 945-949. [DOI:10.5114/aoms.2010.19306]
17. Lahat E, Raziel A, Friedler S, Schieber-Kazir M, Ron-El R. Long-term follow-up of children born after inadvertent administration of a gonadotrophin-releasing hormone agonist in early pregnancy. Hum Reprod 1999; 14: 2656-2660. [DOI:10.1093/humrep/14.10.2656]
18. Tarlatzis BC, Bili H. Safety of GnRH agonists and antagonists. Expert Opin Drug Saf 2004; 3: 39-46. [DOI:10.1517/14740338.3.1.39]
19. Davar R, Rahsepar M, Rahmani E. Comparative study of luteal estradiol pre-treatment in GnRH antagonist protocols and in micro dose flare protocols for poor-responding patients. Arch Gynecol Obstet 2013; 287: 149-153. [DOI:10.1007/s00404-012-2522-0]
20. Eftekhar M, Khalili MA, Rahmani E. The efficacy of recombinant versus urinary HCG in ART outcome. Iran J Reprod Med 2012; 10: 543-548.

Send email to the article author


© 2021 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb